Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 20%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a biopharmaceutical company with a strong presence in the oncology market through its two FDA-approved drugs – Cabometyx and Cotellic – for the treatment of various cancers. The company has consistently exceeded revenue and earnings expectations, driven by solid demand and market share growth for Cabometyx. Exelixis has also been actively repurchasing its stock, indicating confidence in its financial strength and growth prospects. With promising results from ongoing clinical trials and a solid pipeline, Exelixis is well-positioned for future growth and potential acquisitions.

Bears say

Exelixis is facing several challenges that may impact its financial performance, including competition from other drug companies, potential clinical development failures, and pricing and reimbursement changes. While there are opportunities for growth with the development of new products and potential success in clinical trials, there are also significant risks that could prevent the company from achieving its financial forecasts. Additionally, the company's valuation, based on a discounted cash flow analysis, suggests a price target of $54 per share, but this could change depending on the success and challenges faced by the company in the future.

Exelixis (EXEL) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 20% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 15 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.